BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26904994)

  • 21. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.
    Urun Y; Leow JJ; Fay AP; Albiges L; Choueiri TK; Bellmunt J
    Crit Rev Oncol Hematol; 2017 Dec; 120():120-126. PubMed ID: 29198325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
    Choueiri MB; Shen JP; Gross AM; Huang JK; Ideker T; Fanta P
    PLoS One; 2015; 10(6):e0126898. PubMed ID: 26083491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer.
    Huang X; Gao P; Song Y; Sun J; Chen X; Zhao J; Xu H; Wang Z
    BMC Cancer; 2015 Mar; 15():202. PubMed ID: 25880692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis.
    Xuelei M; Jingwen H; Wei D; Hongyu Z; Jing Z; Changle S; Lei L
    Oral Oncol; 2015 May; 51(5):483-92. PubMed ID: 25754170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
    Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
    Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.
    Song P; Yin Q; Lu M; Fu BO; Wang B; Zhao Q
    Exp Ther Med; 2015 Apr; 9(4):1393-1400. PubMed ID: 25780441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of MMP-7 expression in colorectal cancer: a meta-analysis.
    Sun DW; Zhang YY; Qi Y; Zhou XT; Lv GY
    Cancer Epidemiol; 2015 Apr; 39(2):135-42. PubMed ID: 25677090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies.
    Tan X; Wen Q; Wang R; Chen Z
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):1077-1085. PubMed ID: 28910204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
    Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
    Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG; Jang JS; Do JH; Kang JH; Lee GW; Oh SY; Kwon HC; Jun HJ; Lim HY; Lee S; Chi KC; Lee SJ
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):935-44. PubMed ID: 21298384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
    Kao SC; Lee K; Klebe S; Henderson D; McCaughan B; Vardy J; Clarke S; van Zandwijk N
    Clin Lung Cancer; 2013 Mar; 14(2):164-71. PubMed ID: 23085037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological significance of ERCC1 expression in breast cancer.
    Gerhard R; Carvalho A; Carneiro V; Bento RS; Uemura G; Gomes M; Albergaria A; Schmitt F
    Pathol Res Pract; 2013 Jun; 209(6):331-6. PubMed ID: 23702380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.